| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| ln Vitro |
Compared with other related kinases including p38, extracellular signal-regulated kinase (ERK), κB kinase inhibitor (IKK2), protein kinase C, Lck, and 70 kDa ζ-related protein (ZAP70), CC-401 dihydrochloride exhibits at least 40-fold higher selectivity for JNK. In cell-based experiments, 1 to 5 μM of CC-401 dihydrochloride specifically inhibited JNK. CC-401 dihydrochloride is a small molecule that specifically inhibits all three JNK isoforms. CC-401 dihydrochloride competitively binds to the ATP-binding site in JNK, thereby inhibiting phosphorylation of the N-terminal activation domain of the transcription factor c-Jun. The specificity of this inhibitor has been validated in vitro using osmolar stress in the HK-2 human renal tubular epithelial cell line. CC-401 dihydrochloride inhibits sorbitol-induced c-Jun phosphorylation in a dose-dependent manner. However, CC-401 dihydrochloride does not prevent sorbitol-induced phosphorylation of JNK, p38, or ERK [1].
|
|---|---|
| ln Vivo |
Compared with the control group, the p-JNK staining level was moderately increased in the bevacizumab and oxaliplatin treatment groups; the p-cJun content was significantly reduced in the CC-401 treatment group, which is consistent with effective JNK inhibition. The DNA damage level was slightly increased in the CC-401 combined treatment group [2]. CC-401 treatment from day 7 to day 24 slowed the progression of proteinuria, and proteinuria was significantly reduced compared with the untreated group and the carrier group on day 14 and day 21. However, the proteinuria level in the CC-401 treatment group was still increased on day 21 compared with day 5. Renal function impairment, manifested as elevated serum creatinine, was observed in the carrier group and the untreated group on day 24. CC-401 treatment prevented this from occurring [3].
|
| References |
|
| Molecular Formula |
C22H26CL2N6O
|
|---|---|
| Molecular Weight |
461.39
|
| CAS # |
2319601-04-0
|
| Related CAS # |
CC-401 hydrochloride; CC-401
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
C1(C2=CC=CC(OCCN3CCCCC3)=C2)=NNC4=C1C=C(C=C4)C5=NC=NN5.Cl.Cl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1674 mL | 10.8368 mL | 21.6736 mL | |
| 5 mM | 0.4335 mL | 2.1674 mL | 4.3347 mL | |
| 10 mM | 0.2167 mL | 1.0837 mL | 2.1674 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
